A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.

摘要: In a phase II study of 67 patients with upper gastrointestinal carcinomas and measurable disease without previous chemotherapy, we have evaluated the combination intensive course 5-fluorouracil (5-FU) (300 mg/m2/d for five days) doxorubicin (40 mg/m2 on day 1), cisplatin (60 1). Courses were repeated every 5 weeks. Among 26 gastric carcinoma, 50% regression rate was obtained median survival all 9 months. 29 pancreatic 21% 4 Regressions also observed in smaller numbers gallbladder ampulla Vater, as well cholangiocellular carcinoma liver. Toxic reactions usually clinically tolerable consisted primarily nausea, vomiting, stomatitis, diarrhea, leukopenia, alopecia. Phase III studies are progress to place value this experimental regimen into clinical perspective.